IgGenix Funding: $65M Raised, Series B (2023)

IgGenix funding overview

IgGenix is a Biotech company based in South San Francisco, CA. IgGenix has raised $65M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in February 2023. The round record for IgGenix runs through 2023; nothing later has been disclosed. Investors on record include Alexandria Venture Investments, Eli Lilly and Company, Khosla Ventures, Sean Parker, AllerFund. 5 distinct backers are named across the disclosed rounds.

IgGenix at a glance

Total raised: $65M
Latest round: Series B
Latest round date: February 2023
Industry: Biotech
Headquarters: South San Francisco, CA
Notable investors: Alexandria Venture Investments, Eli Lilly and Company, Khosla Ventures, Sean Parker, AllerFund

Frequently asked about IgGenix funding

How much has IgGenix raised?: IgGenix has raised $65M in total disclosed funding across the rounds on record.
Who has invested in IgGenix?: Alexandria Venture Investments, Eli Lilly and Company, Khosla Ventures, Sean Parker, AllerFund are named among the investors backing IgGenix.
What was the latest IgGenix funding round?: The most recent disclosed round is a Series B, announced in February 2023.
Where is IgGenix based?: IgGenix is based in South San Francisco, CA.
What sector does IgGenix operate in?: IgGenix is tracked under Biotech from South San Francisco, CA, with $65M in disclosed funding.
When did IgGenix last raise?: The last disclosed IgGenix round closed in February 2023 at Series B.

Round data for IgGenix is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the Biotech companies in South San Francisco and backer lists below.

IgGenix Funding: $65M Raised, Series B (2023)

IgGenix funding overview

IgGenix at a glance

Frequently asked about IgGenix funding

IgGenix founders (1)

Companies related to IgGenix (40)

Browse related funding lists (6)